Evidence map›Paper›PMID 28434689›Full record

ArticleVaccine2017

Early childhood transmission of hepatitis B prior to the first hepatitis B vaccine dose is rare among babies born to HIV-infected and non-HIV infected mothers in Gulu, Uganda.

E Seremba, J P Van Geertruyden, R Ssenyonga, C K Opio, J M Kaducu, J B Sempa, R Colebunders, P Ocama

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

E SerembaDepartment of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. Electronic address: eseremba@gmail.com.
J P Van GeertruydenGlobal Health Institute, University of Antwerp, Belgium.
R SsenyongaClinical Epidemiology Unit, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
C K OpioDepartment of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
J M KaducuDepartment of Paediatrics, Gulu University School of Medicine, Gulu, Uganda.
J B SempaInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
R ColebundersGlobal Health Institute, University of Antwerp, Belgium.
P OcamaDepartment of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Makerere University · UGUniversity of Antwerp · BEGulu University · UGInfectious Diseases Institute · UG

Funding

NURTURE:Research Training and Mentoring Program for Career Development of Faculty at Makerere University College of Health SciencesD43TW010132 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI SEWANKAMBO, NELSON K · 2015 to 2019
$4.3M
FIC NIH HHS D43 TW010132
6 · The paper itself

Abstract

backgroundHepatitis B (HBV) in sub-Saharan Africa is believed to be horizontally acquired. However, because of the high HBV prevalence in northern Uganda, no hepatitis B vaccination at birth and no access to HBV immunoglobulin, we hypothesize that vertical transmission also could also play an important role. We therefore investigated the incidence of HBV among babies presenting for their first HBV vaccine dose in Gulu, Uganda.

methodsWe recruited mothers and their babies (at least 6-week old) presenting for their postnatal care and first HBV vaccine dose respectively. Socio-demographic and risk factors for HBV transmission were recorded. Mothers were tested for Hepatitis B core antibody (anti-HBc-IgG) and hepatitis B surface antigen (HBsAg). HBsAg-positive sera were tested for hepatitis B e antigen (HBeAg) and HBV viral load (HBVDNA). Babies were tested for HBsAg at presentation and at the last immunization visit. A sample of HBsAg-negative babies were tested for HBVDNA. Incident HBV infection was defined by either a positive HBsAg or HBVDNA test. Chi-square or fisher's exact tests were utilized to investigate associations and t-tests or Wilcoxon rank-sum test for continuous differences.

resultsWe recruited 612 mothers, median age 23years (IQR 20-28). 53 (8.7%) were HBsAg-positive and 339 (61.5%) were anti-HBc-IgG-positive. Ten (18.9%) of the HBsAg-positive mothers were HBeAg-positive. Median HBVDNA levels of HBV-infected mothers was 5.7log (IQR 4.6-7.0) IU/mL with 9 (17.6%) having levels≥10

conclusionVertical transmission does not seem to contribute substantially to the high HBV endemicity in northern Uganda. The current practice of administering the first HBV vaccine to babies in Uganda at six weeks of age may be adequate in control of HBV transmission.

Indexed as

AdultChild, PreschoolCoinfectionDNA, ViralFemaleHepatitis BHepatitis B e AntigensHepatitis B VaccinesHIV InfectionsHumansImmunization ScheduleInfantInfectious Disease Transmission, VerticalMaleMothersPregnancyDNA, ViralHepatitis B e AntigensHepatitis B VaccinesEarly childhoodHepatitis BTransmission

Identifiers

PMID28434689
PMCPMC5529605
OpenAlexW2606266621

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.